165 related articles for article (PubMed ID: 8329804)
1. Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials.
Cooke J; Cairns CJ; Tillotson GS; Conner S; Lewin SK; Nicholls J; Tredree RL; Willis JV; Hitchings CR
Ann Pharmacother; 1993 Jun; 27(6):785-9. PubMed ID: 8329804
[TBL] [Abstract][Full Text] [Related]
2. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.
Amodio-Groton M; Madu A; Madu CN; Briceland LL; Seligman M; McMaster P; Miller MH
Ann Pharmacother; 1996 Jun; 30(6):596-602. PubMed ID: 8792944
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy.
Powers T; Bingham DH
Am J Hosp Pharm; 1990 Aug; 47(8):1781-4. PubMed ID: 2389785
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics.
Grasela TH; Paladino JA; Schentag JJ; Huepenbecker D; Rybacki J; Purcell JB; Fiedler JB
DICP; 1991; 25(7-8):857-62. PubMed ID: 1949945
[TBL] [Abstract][Full Text] [Related]
5. [Study of the cost-effectiveness of sequential antibiotic (ciprofloxacin) therapy].
Ludwig E; Kovács G; Nagy G; Székely E
Orv Hetil; 1997 Nov; 138(48):3043-7. PubMed ID: 9441266
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Caldwell JW; Singh S; Johnson RH
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
[TBL] [Abstract][Full Text] [Related]
7. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.
Balfour JA; Faulds D
Pharmacoeconomics; 1993 May; 3(5):398-421. PubMed ID: 10146890
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
Peacock JE; Pegram PS; Weber SF; Leone PA
Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoepidemiology of ciprofloxacin: analysis of use patterns and cost impact.
Marchbanks CR; Graham KK; Barnes J; Dudley MN
Pharmacotherapy; 1991; 11(1):50-5. PubMed ID: 2020611
[TBL] [Abstract][Full Text] [Related]
10. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
Davis C
Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
[TBL] [Abstract][Full Text] [Related]
11. Ciprofloxacin use under a reserved drug and stepdown promotion program.
Frighetto L; Martinusen SM; Mamdani F; Jewesson PJ
Can J Hosp Pharm; 1995 Feb; 48(1):35-42. PubMed ID: 10141061
[TBL] [Abstract][Full Text] [Related]
12. DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients.
Dydek GJ; Souney PF; Matthews SJ
Hosp Formul; 1992 Feb; 27(2):185-91. PubMed ID: 10116716
[TBL] [Abstract][Full Text] [Related]
13. The role of oral antimicrobials for the management of intra-abdominal infections.
Solomkin JS; Dellinger EP; Bohnen JM; Rostein OD
New Horiz; 1998 May; 6(2 Suppl):S46-52. PubMed ID: 9654311
[TBL] [Abstract][Full Text] [Related]
14. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Naber KG; Allin DM; Clarysse L; Haworth DA; James IG; Raini C; Schneider H; Wall A; Weitz P; Hopkins G; Ankel-Fuchs D
Int J Antimicrob Agents; 2004 Jun; 23(6):596-605. PubMed ID: 15194131
[TBL] [Abstract][Full Text] [Related]
15. Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
Bassaris HP; Chrysanthopoulos CJ; Skouelis AT; Starakis JC
J Chemother; 1989 Jul; 1(4 Suppl):676-7. PubMed ID: 16312588
[No Abstract] [Full Text] [Related]
16. The impact of an intensive antimicrobial control program in a Taiwanese medical center.
Chang MT; Wu TH; Wang CY; Jang TN; Huang CY
Pharm World Sci; 2006 Aug; 28(4):257-64. PubMed ID: 17066241
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.
Partsch DJ; Paladino JA
Ann Pharmacother; 1997 Oct; 31(10):1137-45. PubMed ID: 9337437
[TBL] [Abstract][Full Text] [Related]
18. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: a pre- and post-intervention study.
Ho BP; Lau TT; Balen RM; Naumann TL; Jewesson PJ
BMC Health Serv Res; 2005 Jun; 5():48. PubMed ID: 15987523
[TBL] [Abstract][Full Text] [Related]
19. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial.
Aboltins CA; Hutchinson AF; Sinnappu RN; Cresp D; Risteski C; Kathirgamanathan R; Tacey MA; Chiu H; Lim K
J Antimicrob Chemother; 2015 Feb; 70(2):581-6. PubMed ID: 25336165
[TBL] [Abstract][Full Text] [Related]
20. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected].
Iravani A; Tice AD; McCarty J; Sikes DH; Nolen T; Gallis HA; Whalen EP; Tosiello RL; Heyd A; Kowalsky SF
Arch Intern Med; 1995 Mar; 155(5):485-94. PubMed ID: 7864704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
